165 related articles for article (PubMed ID: 31523745)
21. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.
Poon MC; d'Oiron R; Hann I; Négrier C; de Lumley L; Thomas A; Karafoulidou A; Demers C; Street A; Huth-Kühne A; Petrini P; Fressinaud E; Morfini M; Tengborn L; Marquès-Verdier A; Musso R; Devecioglu O; Houston DS; Lethagen S; Van Geet C; von Depka M; Berger C; Beurrier P; Britton HA; Gerrits W; Guthner C; Kuhle S; Lorenzo JJ; Makris PE; Nohe N; Paugy P; Pautard B; Torchet MF; Trillot N; Vicariot M; Wilde J; Winter M; Chambost H; Ingerslev J; Peters M; Strauss G
Semin Hematol; 2001 Oct; 38(4 Suppl 12):21-5. PubMed ID: 11735106
[TBL] [Abstract][Full Text] [Related]
22. Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders.
Shima M
Ann Hematol; 2023 Jun; ():. PubMed ID: 37391649
[TBL] [Abstract][Full Text] [Related]
23. Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions.
Devecioğlu O; Unüvar A; Anak S; Bilge I; Ander H; Ziylan O
Turk J Pediatr; 2003; 45(1):64-6. PubMed ID: 12718376
[TBL] [Abstract][Full Text] [Related]
24. [Use of recombinant factor VII in Glanzmann thrombasthenia: a case report].
Chabchoub Ben Abdallah R; Trabelsi L; Ben Ameur S; Kammoun F; Boukédi A; Ben Salah M; Ben Hlima N; Mahfoudh A
Arch Pediatr; 2010 Jul; 17(7):1062-4. PubMed ID: 20570498
[TBL] [Abstract][Full Text] [Related]
25. Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?
Laurian Y
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():37-40. PubMed ID: 12214146
[TBL] [Abstract][Full Text] [Related]
26. Weekly low-dose recombinant factor VIIa prophylaxis in Glanzmann thrombasthenia.
Andiç N; Oğuz N; Gündüz E; Kiraz Bulduk T; Üsküdar Teke H
Blood Coagul Fibrinolysis; 2021 Jul; 32(5):349-351. PubMed ID: 33878047
[TBL] [Abstract][Full Text] [Related]
27. A novel approach using ancillary tests to guide treatment of Glanzmann thrombasthenia patients undergoing surgical procedures.
Barg AA; Hauschner H; Misgav M; Lubetsky A; Levy-Mendelowitz S; Livnat T; Avishai E; Rosenberg N; Kenet G
Blood Cells Mol Dis; 2018 Sep; 72():44-48. PubMed ID: 30078718
[TBL] [Abstract][Full Text] [Related]
28. The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders.
Poon MC
Transfus Med Rev; 2007 Jul; 21(3):223-36. PubMed ID: 17572261
[TBL] [Abstract][Full Text] [Related]
29. Perioperative management of a pediatric patient with Glanzmann's thrombasthenia during adenoidectomy.
Duman EN; Saylan S; Cekic B
Rev Bras Anestesiol; 2012 Jul; 62(4):548-53. PubMed ID: 22793971
[TBL] [Abstract][Full Text] [Related]
30. Treatment of inherited platelet disorders.
Seligsohn U
Haemophilia; 2012 Jul; 18 Suppl 4():161-5. PubMed ID: 22726101
[TBL] [Abstract][Full Text] [Related]
31. Disease Burden in Patients with Glanzmann's Thrombasthenia: Perspectives from the Glanzmann's Thrombasthenia Patient/Caregiver Questionnaire.
Duncan A; Kellum A; Peltier S; Cooper DL; Saad H
J Blood Med; 2020; 11():289-295. PubMed ID: 32982527
[TBL] [Abstract][Full Text] [Related]
32. Targeting Tissue Factor Pathway Inhibitor with concizumab to improve haemostasis in patients with Glanzmann thrombasthenia: an in vitro study.
Dubut J; Goin V; Derray C; Huguenin Y; Fiore M
J Thromb Haemost; 2024 Jun; ():. PubMed ID: 38880178
[TBL] [Abstract][Full Text] [Related]
33. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
34. Anti-α
Fiore M; d'Oiron R; Pillois X; Alessi MC
Br J Haematol; 2018 Apr; 181(2):173-182. PubMed ID: 29611179
[TBL] [Abstract][Full Text] [Related]
35. Surgical resection of a sphenoid wing meningioma in a patient with Glanzmann thrombasthenia.
Wertz D; Boveroux P; Péters P; Lenelle J; Franssen C
Acta Anaesthesiol Belg; 2011; 62(2):83-6. PubMed ID: 21919374
[TBL] [Abstract][Full Text] [Related]
36. Recombinant Activated Factor VII (Eptacog Alfa Activated, NovoSeven®) in Patients with Rare Congenital Bleeding Disorders. A Systematic Review on its Use in Surgical Procedures.
Di Minno MND; Ambrosino P; Myasoedova V; Amato M; Ventre I; Tremoli E; Minno AD
Curr Pharm Des; 2017; 23(7):1125-1131. PubMed ID: 28034354
[TBL] [Abstract][Full Text] [Related]
37. Description and Clinical Management of Patients With Glanzmann's Thrombasthenia in a University Hospital, a Referral Center Specialized in Hemostasis, in Bogotá, Colombia.
Solano MH; Chaves K; Casas CP
Cureus; 2022 Jun; 14(6):e25657. PubMed ID: 35785009
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram.
Lak M; Scharling B; Blemings A; Sharifian R; Maleki Z; Daraee A; Arjmand AR; Hedner U
Haemophilia; 2008 Jan; 14(1):103-10. PubMed ID: 18070065
[TBL] [Abstract][Full Text] [Related]
39. Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia.
Yilmaz BT; Alioglu B; Ozyurek E; Akay HT; Mercan S; Ozbek N
Pediatr Cardiol; 2005; 26(6):843-5. PubMed ID: 15690232
[TBL] [Abstract][Full Text] [Related]
40. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues.
Di Minno G; Coppola A; Di Minno MN; Poon MC
Thromb Haemost; 2009 Dec; 102(6):1157-64. PubMed ID: 19967146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
